ZBTB7A and acute myeloid leukemia: Compared with recently published whole-exome, whole-genome, and targeted sequencing data of heterogeneous cohorts of adult and pediatric CBF AML patients from two different research groups [8, 18], we observed a higher prevalence of alterations in signaling pathway genes, in ZBTB7A, JAK and epigenetic modifiers, a discrepancy partially explained by the often low VAF of signaling pathway mutations and the deeper sequencing coverage achieved by our targeted sequencing approach.